Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi63-vi65; doi:10.1093/annonc/mdm227
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cinieri, S
Right arrow Articles by Chetri, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cinieri, S
Right arrow Articles by Chetri, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast and ovarian cancer

Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference

S Cinieri1,2,*, L Orlando3, P Fedele1, A Cusmai1, M D'Amico1, P Rizzo1 and MC Chetri1

1 Medical Oncology Division, Brindisi
2 Ematoncology Division, European Institute of Oncology, Milano
3 Unit of Research Medical Senology, European Institute of Oncology, Milano, Italy

* Correspondence to: Dr S. Cinieri, Medical Oncology Division, ASL BR, Brindisi, Italy. Tel: +39-0831-537218; Fax: +39-0831-537918; E-mail: saverio.cinieri{at}auslbr1.it

Breast cancer detection and staging are constantly evolving as technologies improve. Breast cancer surgery is also undergoing continuous refinement, with the objective being to achieve optimal cosmetic results. Surgery has been combined with intraoperative radiation therapy to achieve the best local-disease control with minimal side-effects. The adjuvant strategy of treatment is a ‘hot’ issue in this ‘scenario’. Every 2 years at St Gallen, a nice and cold town in the north of Switzerland, more of 4000 breast cancer experts arrive from every part of the world, to improve their knowledge in this issue. The Consensus Conference with the discussion of 40 international panelists is the zenith of the conference. This report provides a brief presentation and reflections, immediately at the end of the conference, with the objective being to stimulate ideas regarding what should be done tomorrow.

Key words: adjuvant treatment, breast cancer, St Gallen Consensus Conference


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Ahlin, W. Zhou, M. Holmqvist, L. Holmberg, C. Nilsson, K. Jirstrom, C. Blomqvist, R.-M. Amini, and M.-L. Fjallskog
Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer
Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2501 - 2506.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.